China Sky One Medical, Inc. Provides Business Update

2009-01-15

HARBIN, China, Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today provided an update on its business. "Despite the global economic recession, we continue to experience strong demand for our products in China since they address common everyday ailments and are reasonably priced, with consumers only paying a small portion of the cost while the remainder is covered by healthcare insurance," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Best-selling products such as our Slim Patch continue to do well since consumers are more likely to spend on weight loss products at the expense of other discretionary items. In addition, we have a high degree of customer loyalty, especially with our weight loss products, due to our successful advertising campaign in 2008." "Our pipeline of new drugs is robust and we continue to add new sales agents to keep up with the rapid development of the Chinese pharmaceutical market," said Mr. Yan-Qing Liu. "We are currently looking at even more creative promotional and marketing strategies as we continue to launch a host of new and exciting products in 2009. Overall, we believe that we are well positioned to execute on our growth strategy and look forward to continued strong financial performance." About China Sky One Medical, Inc. China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit . Safe Harbor Statement Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. CONTACT: Mr. Yu-Bo Hao, CFO of China Sky One Medical, Inc., +86-0451-53994069, china_sky_one@yahoo.cn; or Investor Relations, Mr. Crocker Coulson, President of CCG Investor Relations, +1-646-213-1915, crocker.coulson@ccgir.com Web site:

机构